The Dilemma of TP53 Codon 72 Polymorphism (rs1042522) and Breast Cancer Risk : A Case-Control Study and Meta-Analysis in The Iranian Population by Afzaljavan, Fahimeh et al.
185 Cell J, Vol 22, No 2, July-September (Summer) 2020
Original Article
The Dilemma of TP53 Codon 72 Polymorphism (rs1042522) and 
Breast Cancer Risk: A Case-Control Study and Meta-Analysis
 in The Iranian Population
Fahimeh Afzaljavan, Ph.D.1, 2#, Negin Chaeichi Tehrani, B.Sc.1#, Mahdi Rivandi, D.V.M.1, 2#, Saeed Zarif 
Ghasemian, B.Sc.2, 3, Elham Vahednia, M.Sc.1, Reza Khayami, B.Sc.4, Mohammad Abavisani, B.Sc.2, 
Alireza Pasdar, M.D., Ph.D.1, 5*
1. Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran
2. Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3. Department of Radiology Technology, Faculty of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran
4. Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran
5. Division of Applied Medicine, Medical School, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK
#The first three authors equally contributed to this work.
*Corresponding Address: P.O.Box: 917794-8564, Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad 
University of Medical Science, Mashhad, Iran
Email: pasdara@mums.ac.ir
 
Received: 14/October/2018, Accepted: 9/March/2019
Abstract
Objective: Mutations of TP53 as a tumor suppressor gene are frequently observed in different types of cancer. A 
codon 72 polymorphism located on exon 4 with two alleles encoding either Proline (CCC) or Arginine (CGC) has been 
indicated as a common variation in association with cancers. Controversial results have been reported regarding the 
association of allelic polymorphism of codon 72 of TP53 gene and breast cancer risk in Iranian patients. Therefore, a 
case-control study was designed. A meta-analysis was also carried out to provide evidence of association between this 
variation and breast cancer in Iran, based on all available published data.  
Materials and Methods: In this case-control study, blood sample of 622 participants, including 308 breast cancer 
cases and 314 controls were collected. Genotyping for rs1042522 was conducted by Allele Specific polymerase chain 
reaction (AS-PCR). In order to set a meta-analysis study, PubMed, Scopus and ISI Web of Knowledge and Persian 
databases were searched to explore relevant studies, published up to September 2018, containing information on 
TP53 polymorphism and the risk of breast cancer in Iran. Statistical analysis was performed using SPSS 16.0 and 
MetaGenyo.                
Results: All retrieved available data as well as the results of our current study were consisted of 1965 breast cancer 
cases and 1999 healthy controls. No significant difference was observed in allele frequencies between groups (P=0.90) 
in our study. The cumulative results did not also show any association between rs1042522 and breast cancer risk on 
the dominant (P=0.61) and recessive (P=0.89) models.                        
Conclusion: These findings cannot support contribution of rs1042522 polymorphism to breast cancer risk in an Iranian 
population. Future larger studies may help confirm this finding with a greater power.    
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Introduction 
Breast malignancy is among the major types of cancer 
and the universal cause of cancer death in women. The 
incidence of breast cancer in western populations is 
significantly higher than other populations. However, 50% 
of new cases and approximately 60% of deaths caused by 
breast cancer occur in developing countries (1). Breast 
cancer is one of the most commonest cancers affecting 
Iranian women, though the epidemiology of breast cancer 
in Iran has not yet been fully investigated (2). 
Based on epidemiological studies, a number of factors 
have been identified associating with increased risk of 
breast malignancies. These factors are not necessarily 
causes of breast cancer and they can be subcategorized 
in both genetic and environmental factors, increasing 
liability of the breast cancer. Association studies, whereby 
the relations of certain markers with the disease are 
investigated prominently in case-control designs, are of 
crucial importance to dissect the genetic basis of common 
multifactorial disorders, such as breast cancer. Based on 
this, several candidate genes have been analyzed so far in 
case-control studies.
One of the highest involved genetic factors in the risk 
of breast cancer is the tumor suppressor gene, TP53. 
The corresponding protein, P53, has a role in cell cycle 
regulation including cell growth and division, apoptosis, 
DNA repair and the maintenance of genome stability and 
its mutations have been commonly observed in different 
types of cancer (3, 4). Dysfunction of the P53 signaling 
pathway is an important hallmark of different malignancies 
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(5). Numerous single nucleotide polymorphisms (SNPs), 
somatic and germ line mutations are located at the TP53 locus. 
Polymorphisms in this gene may affect the susceptibility 
to cancer development in the way of varying the normal 
functions of P53. Since many of these variations have been 
found in intronic loci, they cannot affect the biology of cancer. 
However, they may be used as markers in dissecting 
genetic basis of multifactorial diseases. Previously, limited 
numbers of TP53 polymorphisms have been studied 
in relation with biochemical and biological functions 
and in association with cancer risk. The TP53 codon 72 
polymorphism (C/G) has been located at the exon 4 of 
this gene and encodes Proline (CCC) or Arginine (CGC). 
Association of this polymorphism with susceptibility to 
several forms of cancer has been identified (6). According 
to research on different populations, genotype frequencies 
have been found to largely differ with ethnicity changes 
(7). The difference in the primary structure of P53 
protein results in different biochemical functions. The 
potential role of Arg variant in the induction of apoptosis 
pathway has been confirmed in a previous research (8). 
Furthermore, "Pro" variant can block cell cycle pathway 
progression toward the repair of  DNA damage (9). 
Association of the TP53 codon 72 polymorphism and 
susceptibility to breast cancer has been considered in 
several regions of Iran. These case-control studies did 
not indicate consistent results, likely due to the small 
sample sizes with limited power. A meta-analysis along 
with combining the different results and small data, can 
achieve a reasonable level of significance and an increase 
in power of results. In the present study, we examined 
association of rs1042522 and breast cancer susceptibility 
in the North-East of Iran and a meta-analysis was 
performed to quantitatively assess effect of the TP53 
codon 72 polymorphism on risk of breast cancer in Iran.
Materials and Methods 
Population study
In this case-control study, 308 breast cancer cases and 
314 healthy controls with no sign of breast cancer or history 
of malignant breast disease participated in this association 
study. The important demographics and histopathological 
data were obtained from a questionnaire. The Ethics 
Committee of the Mashhad University of Medical Science 
approved this study (ethical approval number: IR.MUMS.
fm.REC.1394.472) and all of the participants signed the 
written informed consent. 
DNA extraction and genotyping analysis
The salting out method was used to extract DNA from 
peripheral blood samples. Genotyping was performed using 
Allele specific polymerase chain reaction (AS-PCR) methods 
(10). We used primers from the previous study (11) and the 
sequence of four primers (synthesis by metabion international 
AG, Germany) was shown as follows:
Arginine-based (G) allele: 
F: 5´-TCCCCCTTGCCGTCCCAA-3´
R: 5´-CTGGTGCAGGGGCCACGC-3´ 
Proline-based (C) allele:
F: 5´-GCCAGAGGCTGCTCCCCC-3´
R: 5´-CGTGCAAGTCACAGACTT-3´
PCR was done in a final volume of 10 µl reaction for each 
allele containing: Taq DNA Polymerase 2x Master Mix 
RED (Ampliqon, Denmark), 1 μl genomic DNA (200-300 
ng), 1 µl of each primer (10 µM, Metabion International 
AG, Germany) and adequate DNase free water (Sinaclon, 
Iran). Amplification temperature stages were performed 
for 5 minutes at 95˚C and then 35 cycles including 30 
seconds at 94˚C, 30 seconds at 63˚C, 30 seconds at 72˚C, 
followed by 7 minutes at 72˚C in a Veriti 96 well PCR 
Thermal Cycler (Thermo Fisher Scientific).
Identification of studies for meta-analysis
The original publications, reporting association 
between TP53 codon 72 polymorphism and breast 
cancer risk before September 2018, were gathered by 
searching Scopus, PubMed and ISI Web of Knowledge 
databases. The Persian articles and conference abstracts 
were also explored by searching SID, Iranmedex, 
Magiran, Medlib and Google. The references of 
retrieved articles were also investigated to discover 
other related studies. The terms of "TP53" and "genetic 
variant", "genetic variation" or "polymorphism" and 
"breast cancer", "breast carcinoma", "breast tumour" 
or "breast tumor" and "Iran" or "Iranian" were used to 
search for the articles of interest. Case-control studies 
were selected for the analysis. 
Data extraction
A meta-analysis was designed according to PRISMA 
guidelines (12). Features of the selected studies were 
independently extracted by two authors. For each eligible 
study, first author, date of publication, number of cases 
and controls, study population (region), frequency of all 
genotypes for two groups, allele incidence and Hardy-
Weinberg equilibrium (HWE) in control groups were 
extracted or calculated and ultimately the results were 
reviewed by the third investigator. 
Statistical analysis
Chi-square test and logistic regression models were 
performed to find association between histopathological 
or demographic criteria and genotypes of rs1042522. 
In the meta-analysis study, frequency of two alleles 
was calculated for the case and control groups in 
each experiment. HWE test using the X2 statistic was 
evaluated by analysis of the genotype frequencies 
in the controls. Association was measured initially 
using both random-effect and fixed-effect models. 
However, since the random-effect method proposes 
heterogeneity, this method was considered as the main 
approach. The strength of association between TP53 
codon 72 polymorphism and risk of breast cancer was 
measured by odds ratios (ORs) with 95% confidence 
intervals (CIs).
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The risk for the genotypes GC and CC was compared 
to the GG homozygote, as the wild-type genotype. 
Furthermore, according to the dominant and recessive 
models, the risk of Arg-carriers (GC+GG) versus CC 
genotype and Pro-carriers (CC+GC) versus GG genotype 
were evaluated, respectively.
Heterogeneity was evaluated by the Q-test and I2 index. 
Probability of publication bias was checked by the funnel 
plot and Egger’s test for all genetic models. Random 
effects model was used to analyze the data.
Meta-analysis was carried out using MetaGenyo [Pfizer-
University of Granada-Junta de Andalucía Centre for 
Genomics and Oncological Research (GENYO), Spain] 
(13). All other statistical analyses were carried out using 
SPSS version 16.0 (SPSS Inc., USA). A P value of less 
than 0.05 was considered statistically significant.
Results
Characteristics of the population study
A total of 308 breast cancer women, out of 622 samples, and 
314 healthy controls were enrolled in this study. The average 
age of case and control groups were 47.80 ± 10.90 and 44.15 ± 
12.07 years, respectively, with a significant difference between 
the groups (P<0.001). Furthermore, menopausal status was 
considered as peri- and pre-menopausal, compared to post-
menopausal individuals. The control group was younger than 
cases, and therefore most of the patients typically belonged to 
the post-menopausal group. The difference between groups 
was significant (P<0.001).   
Body mass index (BMI), as a continuous and categorical 
variable, was compared between these groups. Mean 
BMI was higher in the patient cases than in controls and a 
significant difference was observed (P<0.001). Moreover, 
by categorizing patients, it was distinguished that a large 
number of cases were included in BMI ≥25 category.
The history of lactation (P<0.01), history of other cancers 
(P<0.001) and family history of cancer (P<0.001) were 
also significantly different between patients and healthy 
controls. Table 1 shows the most important demographic 
characteristics of the case and control groups.
Association between rs1042522 and the risk of breast 
cancer in the Northeast of Iran
Genotypic distribution of the rs1042522 in our 
study conforms HWE (P>0.05). The C allele (Pro) 
frequency, as the minor allele was 24% in the cases, 
compared to 23.7% in the controls. According to this 
data, no association was found between case and control 
groups for allele frequency (P=0.90). The most frequent 
genotype for rs1042522 was GG (Arg/Arg) in both case 
(60.7%) and control (60.2%) groups. Genotype frequency 
did not show any significant difference between these two 
groups (P>0.05). Moreover, dominant and recessive 
models did not indicate any association with the risk 
of breast cancer. Results have been shown in Table 2.  
Adjustment for confounding factors including age, BMI, 
history of cancer, family history of cancer and history of 
lactation did not change the results.
Meta-analysis
133 articles were identified from different databases 
by two authors, individually. After matching the data, 
discrepancies were reanalyzed by the third author. 42 
articles were similar between databases. Therefore, 91 
articles were assessed for eligibility. 73 studies were not 
related to the subject. Furthermore, two records were 
not designed as the case-control study. After excluding 
duplicated, unrelated and improperly designed papers, 16 
case-control studies, concerning the association between 
TP53 codon 72 polymorphism and breast cancer, were 
included in the meta-analysis. The selection process has 
been demonstrated in Figure 1.  
 Table 1: Results of the association analysis of demographic
characteristics between breast cancer cases and healthy group
Characteristics Cases Controls P value
n (%) n (%)
Age (Y)
  ≤40 74 (25.8) 138 (44.4)
  >40 213 (74.2) 173 (55.6) <0.001
   Mean 47.80 ± 10.90 44.15 ± 12.07 <0.001
Menopausal status
  Peri and premenopausal 86 (45.3) 217 (78.9)
  Postmenopausal 104 (54.7) 58 (21.1) <0.001
Body mass index (kg/m2)
   <25 80 (31.2) 154 (51.2)
   ≥25 176 (68.8) 147 (48.8) <0.001
   Mean 27.59 ± 5.06 25.20 ± 4.12 <0.001
Abortion
   Yes 172 (67.5) 151 (65.1)
   No 83 (32.5) 81 (34.9) 0.63
History of lactation
   Yes 246 (91.4) 223 (97.4)
   No 23 (8.6) 6 (2.6) <0.01
Family history of cancer
   Yes 172 (60.8) 229 (73.9)
   No 111 (39.2) 81 (26.1) <0.001
History of other cancer
   Yes 20 (7.2) 3 (1.0)
   No 259 (92.8) 301 (99.0) <0.001
Data are presented as mean ± SD or n (%).
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Table 2: Distribution of the genotypes and allele frequency of rs1042522 polymorphism in breast cancer cases and controls
Genetic analysis model Number of case (%)  Number of control (%) P value OR (95% CI)
Genotypes
   GG 187 (60.7) 189 (60.2) Reference
   GC 94 (30.5) 101 (32.2) 0.73 0.94 (0.67-1.33)
   CC 27 (8.8) 24 (7.6) 0.67 1.38 (0.63-2.04)
Dominant
   GG+GC 281 (91.2) 290 (92.4) Reference
   CC 27 (8.8) 24 (7.6) 0.61 0.86 (0.48-1.53)
Recessive
   GG 187 (60.7) 189 (60.2) Reference
   GC+CC 121 (39.3) 125 (39.8) 0.89 0.98 (0.71-1.35)
Allele
   G 468 (76.0) 479 (76.3) Reference
   C 148 (24.0) 149 (23.7) 0.90 1.02 (0.78-1.32)
OR; Odd ratio and CI; Confidence interval.
Fig.1: Flowchart of the search strategy and selection of studies. After searching in main databases, with removing 117 studies due to duplication, improper 
subjects and no case-control design, 16 articles remanied to be included in the mata-analysis.
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Data extraction
Overall the data included 1965 breast cancer subjects 
and 1999 healthy people. Diversity in the sample size, 
ranged from 42 to 314 individuals, was found between 
studies. Moreover, genotyping methods were different 
between projects. Nine studies used the AS-PCR method 
and seven studies were performed by the PCR-restriction 
fragment length polymorphism (PCR-RFLP) method. 
Although the main source of DNA template was blood in 
many studies, one study had been performed on normal 
and cancerous tissues and five projects had used tissue 
samples for patient’s genotyping and blood samples for 
healthy groups.
Frequency of the 72 Pro allele varied in the control 
participants, from 30 to 60%, depending on the geographical 
region. Apart from the four studies, HWE was confirmed for 
frequency of TP53 codon 72 genotypes in the control group. 
The results have been shown in Table 3.
Pooled allele frequencies did not significantly differ 
between Iranian patients and healthy controls. Results 
confirmed a lack of association between the TP53 codon 
72 and susceptibility to breast cancer in all genetics 
models. This finding did not vary after removing studies 
with no HWE data. 
Publication bias was evaluated by the analysis of 
Begg’s funnel plots and Egger’s test for all genetic 
models. All plots indicated some evidence of publication 
bias, however, this finding was not significant (P>0.05, 
plots have not been shown). According to the P value of 
heterogeneity, we found high incidence of heterogeneity 
between the studies in different genetic models (P< 0.01). 
Results have been shown in Table 4.  
Table 3: Extracted data from the selected studies
Study Year Region Type of samples Method Sample size Genotype frequency p HWE Allele frequency (%)
Cases Controls Cases Controls
Cases Controls Cases Controls A/A A/P P/P A/A A/P P/P G C G C
Faghani et al. (14) 2007 Isfahan Tissue Blood AS-PCR 51 51 44 6 1 22 27 2 0.19 92.1 7.8 69.6 30.4
Khadang et al. (15) 2007 Shiraz Blood Blood AS-PCR 221 205 83 109 29 75 90 40 0.39 62.2 37.8 58.5 41.5
Faghani et al. (16) 2008 Isfahan Tissue Blood AS-PCR 96 96 68 21 7 35 44 17 0.88 81.7 18.2 59.4 40.6
Kazemi et al. (17) 2009 North of 
Iran
Tissue Blood AS-PCR 42 60 6 30 6 12 45 0 0 50 50 39.5 60.5
Doosti et al. (18) 2011 Isfahan Blood Blood PCR-RFLP 135 140 52 70 13 36 82 22 0.09 64.4 35.6 55 45
Hossein Pour Feizi et al. (19) 2012 Tabriz Blood Blood AS-PCR 126 99 56 44 26 30 50 19 0.97 61.9 38.1 55.6 44.4
Golmohammadi and Namazi 
(20)
2013 Sabzevar Blood Blood AS-PCR 80 80 29 49 2 15 51 14 0.04 66.8 33.2 50.6 49.4
Rouhi Boroujeni et al. (21) 2013 Isfahan Blood Blood PCR-RFLP 135 150 27 102 6 36 93 21 0.01 57.8 42.2 55 45
Behfarjam et al. (22) 2013 Mahabad Blood Blood PCR-RFLP 25 30 9 14 2 9 17 4 0.66 64 36 58.3 42.7
Sheikhpour and Taghipour 
Zahir (23) 
2014 Yazd Blood Blood AS-PCR 104 104 51 31 22 22 54 28 0.91 63.9 36.1 47.1 52.9
Saadatian et al. (24) 2014 Tabriz Blood Blood PCR-RFLP 100 100 22 48 30 13 63 24 0.02 46 54 44.5 55.5
Gohari-Lasaki et al. (25) 2015 Tabriz Blood Blood PCR-RFLP 100 100 31 48 21 31 57 12 0.18 55 45 59.5 40.5
Ahangar Oskouee et al. (26) 2015 Tabriz Tissue Tissue PCR-RFLP 65 65 21 40 4 48 13 4 0.11 63.1 36.9 83.8 16.2
Rajabi Firoozabadi et al. (27) 2016 Yazd Blood Blood AS-PCR 90 83 10 45 35 21 37 25 0.62 36.1 63.9 47.5 52.5
Moradinasab et al. (28) 2017 Bushehr Blood Blood PCR-RFLP 144 162 46 68 30 50 90 22 0.18 55.6 44.4 58.6 41.4
Pouladi et al. (29) 2018 Tabriz Tissue Blood AS-PCR 143 160 63 54 26 54 74 32 0.77 62.9 37.1 56.8 43.2
Our study 2018 Northeast 
of Iran
Blood Blood AS-PCR 308 314 187 94 27 189 101 24 0.14 76 24 76.2 23.8
Total (17 studies) 1965 1999 805 873 287 698 988 310 0.43 63.4 36.6 59.7 40.3
AS-PCR; Allele specific polymerase chain reaction, RFLP; Restriction fragment length polymorphism, and HWE; Hardy-Weinberg.
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 Table 4: Analysis of the association between TP53 codon 72 polymorphism and breast cancer risk in different genetic models, the test of heterogeneity
and publication bias
Model Test of association Test of heterogeneity Publication bias
OR (95% CI) P value Model P value I2 P value (Egger’s test)
Allele contrast (G vs. C) 1.18 (0.96-1.47) 0.13 Random <0.001 0.80 0.63
Recessive model (GG vs. GC+CC) 1.34 (0.95-1.89) 0.10 Random <0.001 0.83 0.73
Dominant model (GG+GC vs. CC) 1.15 (0.84-1.56) 0.38 Random <0.01 0.58 0.51
Over dominant (GC vs. GG + CC) 0.79 (0.58-1.06) 0.12 Random <0.001 0.79 0.50
Pairwise 1 (GG vs. CC) 1.38 (0.93-2.04) 0.11 Random <0.001 0.67 0.83
 Pairwise 2 (GG vs. GC) 1.36 (0.95-1.95) 0.10 Random <0.001 0.82 0.66
Pairwise 3 (GC vs. CC) 1.00 (0.72-1.36) 0.97 Random <0.01 0.55 0.63
OR; Odd ratio and CI; Confidence interval.
Discussion
The mortality rate in comparison with the rate of breast 
cancer is higher in developing rather than developed 
countries, due to the early detection of diseases using 
genetic biomarkers in the latter countries. SNPs are a 
good example of these biomarkers. The TP53 codon 72 
polymorphism (rs1042522) has been reported to have an 
association with the susceptibility to cancer in the different 
populations. Due to the lack of association studies with 
sufficient sample sizes and strong conclusions to assess 
correlation between rs1042522 and risk of breast cancer 
development, we conducted the case-control study on 622 
breast cancer patients and controls in the northeast of Iran. 
A previous meta-analysis study without any ethnicity 
restriction showed association of TP53 codon 72 
polymorphism with breast cancer risk in the recessive 
model. This study only confirmed a significant difference 
in the allelic model of an Asian population (14). However, 
involvement of other risk factors in this association was 
suggested. Genetic background and ethnicity are amongst 
those influential factors that may change association status. 
Since several case-control studies have reported different 
results about the association between rs1042522 and breast 
cancer risk in Iran, the need for a comprehensive analysis 
was warranted. In order to elucidate this inconsistent 
conclusion, a meta-analysis was performed to examine 
the association between TP53 codon 72 polymorphism 
and breast cancer risk in Iran, by reviewing all published 
studies with conflicting results. The final analysis included 
a total of 1965 breast cancer patients and 1999 healthy 
individuals, as the control group, to evaluate the existence 
or absence of any association.
Our pooled data from 17 case-control studies, meeting the 
inclusion criteria, confirmed lack of association between 
risk of breast cancer and TP53 codon 72 polymorphism 
in Iran. The heterogeneity amongst the studies has 
been pointed out in the analysis. Ethnicity, minor allele 
frequency, sample size, genotyping methods, source of 
DNA and disease phenotypes may be regarded as the 
source of such heterogeneity. However, we acknowledge 
that we focused on studies considering germline variants 
as risk factors, there are some studies which may have 
investigated the somatic variants to provide a catalogue 
of tumoral genetic variations (15, 16).
Our results indicated that pooled control samples 
followed HWE. Four studies failed to show HWE, 
however, when they were excluded from the analysis, the 
overall results were not significantly changed (data has 
been shown in the Table S1) (See Supplementary Online 
Information at www.celljournal.org). 
Pooled allele frequencies were 0.60 and 0.63 for G in 
the control and case groups, respectively. According to 
NCBI and OMIM data, C allele is the ancestral allele 
coding Proline. Allele frequency of C is higher than G 
in the general population, however, population based 
studies indicate high heterogeneity related to the C and G 
allele frequencies. According to some online databases, the 
frequencies vary between 0.9 for C and 0.1 for G in Oceania 
and inversely 0.2 and 0.8 for C and G respectively in Europe, 
suggesting a powerful ethnic influence (17). In our study, 
minor allele was C allele in the pooled data with a frequency 
of 0.37 and 0.40 in the respectively controls and cases.
The results did not show a significant difference between 
allele frequencies in patients and healthy subjects (P in 
multiplicative model ≤0.12). This finding was also seen 
in recessive and dominant models. Statistical evidence 
from other meta-analysis studies have indicated this 
polymorphism may have a potential effect on breast (14) 
and ovarian cancer risks (18) in the pooled data as well 
as a subgroup of Asian and Caucasian populations. On 
the other hand, in another previously conducted meta-
analysis (with no ethnicity preference) no association 
between TP53 codon 72 polymorphism with breast cancer 
(19) and cervical cancer (20) risks was reported. 
The pooled data indicated that allele frequency difference 
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between cases and controls was about 3%. Therefore, it is 
proposed to evaluate the association between TP53 codon 
72 polymorphism and risk of breast cancer with a power 
of 80%; in other words 4129 individuals is proposed for 
each group in future studies. In our study the overall 
power was calculated as 50% which may not support the 
evidence of this association. Designing proper studies 
with adequate sample sizes will provide more valuable 
evidence for this association.
Conclusion
Our results showed that TP53 codon 72 polymorphism 
may not influence the overall risk of breast cancer in an 
Iranian population. By that means, there is no association 
between TP53 codon 72 polymorphism and breast cancer 
risk in the Iranian population of this meta-analysis. Several 
included studies had limited sample size and they were 
underpowered. To assess this association more precisely, 
well-designed case-control studies with adequate sample 
sizes are still necessary. 
Molecular classification, as well as evaluating the effect 
of other polymorphisms and environmental factors, such 
as alcohol consumption and tobacco smoke, should also 
be considered. Characteristics of different individuals, 
including premenopausal or postmenopausal status, 
metabolic index, family history, epistasis and clinical 
course are also important. 
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